ArticleFrontiers in pediatrics2026
Efficacy of interventions in peripheral arterial and venous malformations of the limbs in children: protocol for a systematic review.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Peripheral arteriovenous malformations (pAVMs) of the limbs are common in children, with distinct clinical features and high intervention difficulty. Existing research on its interventions is controversial due to non-standardized criteria, small-sample uncontrolled studies and inconsistent efficacy evaluation, leaving clinicians without high-quality evidence-based guidance. Methods and analysis: This study will conduct a PROSPERO-registered systematic review, searching PubMed, Embase and other databases for relevant clinical studies. Two researchers will independently screen literature, extract data and assess evidence quality via GRADE. RevMan 5.4 will be used for qualitative and quantitative statistical analysis, with subgroup and sensitivity analyses to explore heterogeneity. Primary outcome is short-term symptom improvement rate within 3 months post-intervention; secondary outcomes include adverse event incidence and quality of life. Ethics and dissemination: Ethical approval is not required because this study is a secondary analysis of existing data. We will disseminate the findings through peer-reviewed publications. Clinical Trial Registration: PROSPERO (CRD420261326988).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.